Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment
2024/01/24 by Jeffrey M. Holzbeierlein, Brooke R. Bixler, David Buckley +9 · 378 citations
Medicine · #Bladder and Urothelial Cancer Treatments #Bladder cancer #Cancer #Gerontology #Guideline #Internal medicine #Library science #Medicine #Pathology #Ureteral procedures and complications #Urinary and Genital Oncology Studies #Urology
paper · doi:10.1097/ju.0000000000003846
published in The Journal of Urology 211(4), 533-538 (Lippincott Williams & Wilkins)
openalex publication_date 2024/01/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
Abstract
PURPOSE: The purpose of this American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: In 2023, the NMIBC guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published guidelines in an effort to maintain currency. The amendment allowed for the incorporation of additional literature released since the previous 2020 amendment. The updated search gathered literature from July 2019 to May 2023. This review identified 1918 abstracts, of which 75 met inclusion criteria.When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) in support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. RESULTS: Updates were made to statements on variant histologies, urine markers after diagnosis of bladder cancer, intravesical therapy, BCG maintenance, enhanced cystoscopy, and future directions. Further revisions were made to the methodology and reference sections as appropriate. CONCLUSIONS: This guideline seeks to improve clinicians' ability to evaluate and treat patients with NMIBC based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.
Citations
Cited by
- Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance
- Foley Catheter Management
- Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
- Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer
- Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review. [europepmc]
- Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer. [europepmc]
- Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review. [europepmc]
- Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. [europepmc]
- Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers. [europepmc]
- Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. [europepmc]
- Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024. [europepmc]
- Anticancer role of flubendazole: Effects and molecular mechanisms (Review). [europepmc]
- Integrated multicenter deep learning system for prognostic prediction in bladder cancer. [europepmc]
- Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). [europepmc]
- Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis. [europepmc]
- Review of BCG immunotherapy for bladder cancer. [europepmc]
- pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for Bladder Cancer-Associated microRNAs. [europepmc]
- Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial. [europepmc]
- Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer. [europepmc]
- Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin-Treated Nonmuscle-Invasive Bladder Cancer. [europepmc]
- Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. [europepmc]
- Urothelial carcinoma: Perioperative considerations from top to bottom. [europepmc]
- Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes. [europepmc]
- Hypoxia-induced HIF-1α/VASN promotes bladder cancer progression. [europepmc]
- TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. [europepmc]
- Unraveling the potential: mRNA therapeutics in oncology. [europepmc]
- The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review. [europepmc]
- Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. [europepmc]
- Field-effect-informed urine liquid biopsy for bladder cancer. [europepmc]
Related